Table 1.
Recent clinical trials (2020–2021) conducted in thyroid cancer.
| S No. | Phase | Drugs | Type of Thyroid Cancer | Target | Clinical Trial | Status |
|---|---|---|---|---|---|---|
| 1 | Phase 3 | Selpercatinib + Cabozantinib + Vandetanib | MTC | MET, RET, VEGFR1/2/3, FLT3, KIT, TRKB, AXL | NCT04211337 | Recruiting |
| 2 | Phase 3 | Pralsetinib + Cabozantinib + Vandetanib | RET-mutated MTC | Mutated-RET, VEGFR1/2/3, FLT3, KIT, TRKB | NCT04760288 | Not yet recruiting |
| 3 | Phase 2 | Cabozantinib (40 mg) | ATC | MET, RET, VEGFR1/2/3, FLT3, KIT, TRKB | NCT04400474 | Recruiting |
| 4 | Phase 2 | Dabrafenib + Trametinib + PDR001 | FTC, PTC | BRAF, MAP2K; MAPK/ERKK, MEK1/2 | NCT04544111 | Recruiting |
| 5 | Phase 2 | Lenvatinib | DTC, ATC | VEGFR2 | NCT04321954 | Not yet recruiting |
| 6 | Phase 2 | Lenvatinib + Pembrolizumab | mTC, PDTC, Stage IVB ATC, | VEGFR2, mutant and fusion products of RET | NCT04171622 | Not yet recruiting |
| 7 | Phase 2 | Cemiplimab + Dabrafenib + Trametinib | BRAF-V600 mutated ATC | BRAF, ME2K, MEK1/2 | NCT04238624 | Recruiting |
| 8 | Phase 2 | Dabrafenib + Trametinib | RAI-refracted FTC | BRAF, ME2K, MEK1/2 | NCT04554680 | Recruiting |
| 9 | Phase 2 | Dabrafenib + Trametinib | BRAF-ATC | BRAF, ME2K, MEK1/2 | NCT04739566 | Recruiting |
| 10 | Phase 1 | Dabrafenib + Trametinib + IMRT * | BRAF-V600Kmutated ATC | BRAF, ME2K, MEK1/2 | NCT03975231 | Recruiting |
| 11 | Phase 1 | Cabozantinib + Nivolumab | Advanced PTC | MET, RET, VEGFR1/2/3, FLT3, KIT, TRKB, PD-1, PD-L1, PD-L2 | NCT04514484 | Recruiting |
* Intensity modulated radiation therapy.